WCLC Voice of China The best solution for immunotherapy resistance.. The efficacy of immunotherapy after EGFR TKI treatment failure

At this year's WCLC conference, a study conducted by Professor Lu Shun's team from the Chest Hospital Affiliated to Shanghai Jiao Tong University explored the best options for patients with oligoprogression after resistance to immunotherapy

Voice of China: Professor Lu Shun's team explores the "best" solution for oligoprogressive patients after immunotherapy resistance

Oligoprogressive disease is an umbrella term

According to the European Organization for Research and Treatment of Cancer (EORTC) consensus, tumor patients can be divided into four progression modes: de novo systemic progression (DNP), repetitive oligoprogression (REO), induced oligoprogression (INO) and repetitive systemic progression (REP).

In the total population, 401 patients had disease progression, with 36.

After immunotherapy resistance, the optimal choice for REO patients may be LAT therapy

Atezolizumab has been approved for patients with advanced NSCLC, but there is currently a lack of research data on atezolizumab for later-line treatment

ML40471 is an open-label, single-arm, multicenter, Phase III study

From June 2019 to August 2020, a total of 101 patients were enrolled in the study and received atezolizumab (second-line and above) treatment, of which 69.

Consistent with previous study data, this study identified further evidence of the clinical benefit of atezolizumab

In Asian populations, about 50% of lung adenocarcinoma patients have EGFR mutations

The study retrospectively screened data from 6020 lung cancer patients treated with PD-1/PD-L1 inhibitors and 1563 lung cancer patients treated with anlotinib in Shanghai Chest Hospital from 2018 to 2021

The median PFS was 4.

Anlotinib combined with PD-1 inhibitor is a potential and promising treatment option for the later-line treatment of patients with EGFR TKI-resistant lung adenocarcinoma, which is worthy of further exploration in prospective trials
.

Reference
1.
OA11.
05 - Treatment Strategies Based on Different Oligoprogressive Patterns after Immunotherapy Resistance in Advanced NSCLC2.
EP08.
01-033 - ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC

3.
EP08.
01-102 - Anlotinib Combined with PD-1 Inhibitors May Benefit Advanced Non-small Cell Lung Cancer Patients After Failure of EGFR-TKI Therapy

Editor: Xiaoyuan Typesetting: Xiaoyuan
Execution: Youshi